Servier invests over 20% of revenue from brand-name medicines in R&D each year.
Research & Development
RESEARCH & DEVELOPMENT
Picking up the pace of research and efforts to develop new therapeutic solutions
Our aim is clear—to pick up the pace of research and efforts to develop new therapeutic solutions guided by a long-term vision.
Day in, day out, our teams work tirelessly to discover and develop medicines where patient needs are greatest.
Investing heavily in R&D
Servier’s governance model headed by a non-profit foundation aligns perfectly with the long-term perspective required for research and development. Our independence from market forces means we can invest heavily in R&D to innovate and develop new medicines.
Boosting efficiency in R&D to benefit patients
Our R&D model is built around a number of core elements that will drive progress and therapeutic performance. Firstly, we put the patient at the heart of everything we do in R&D, which is why we focus on translational medicine. This collaborative approach serves to better understand the disease and speed up the process of moving candidate drugs through the various clinical phases. It relies in particular on the use of innovative biomarkers that provide information about the effect of treatment on the disease for different groups of patients.
Opening the door to new discoveries
In order to move to the next level, we drive fresh momentum by concentrating our efforts in key therapeutic areas.
In oncology, we target hard-to-treat cancers; in immune-inflammatory and neurodegenerative diseases, we primarily address specific diseases to respond to the as yet unmet medical needs of patients; and finally in cardiometabolism, we focus on innovation in life cycle management. We therefore capitalize on our existing medicines and expertise in incremental innovation, in particular by developing single pill combinations.
Over 50% of the overall R&D budget is allocated to research into cancer treatments